

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6709578

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
OLGA VASILJEVA	08/26/2014
ELIZABETH-EDNA MARY MENENDEZ	08/26/2014
RECEIVING PARTY DATA	
Name:	CYTOMX THERAPEUTICS, INC.
Street Address:	151 OYSTER POINT BOULEVARD, SUITE 400
Internal Address:	ATTN: PATENT DEPARTMENT
City:	WASHINGTON
State/Country:	D.C.
Postal Code:	20004
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17246167
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 937-1327
Email:	lharveyjones@cooley.com, zIPPatentDocketingMailboxUS@Cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	1299 PENNSYLVANIA AVE., N.W., SUITE 700
Address Line 2:	ATTN: PATENT DEPARTMENT
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	CYTM-024/C02US 322001-260
NAME OF SUBMITTER:	TATHAGAT DUTTA RAY
SIGNATURE:	/Tathagat Dutta Ray/
DATE SIGNED:	05/14/2021
Total Attachments: 6	
source=CYTM-024-C02US Assignment#page1.tif	
source=CYTM-024-C02US Assignment#page2.tif	

source=CYTM-024-C02US Assignment#page3.tif

source=CYTM-024-C02US Assignment#page4.tif

source=CYTM-024-C02US Assignment#page5.tif

source=CYTM-024-C02US Assignment#page6.tif

ASSIGNMENT

Olga Vasiljeva, and Elizabeth-Edna Mary Menendez (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled **Compositions and Methods For Detecting Protease Activity In Biological Systems**, and which is a:

- (1) provisional application
(a) to be filed herewith; or
(b) bearing Application No. _____, and filed on _____;
- (2) non-provisional application
(a) to be filed herewith; or
(b) bearing Application No. 14/147,324, and filed on 01/03/14; and/or
- (3) PCT application
(a) bearing Application No. _____, and filed on _____.

WHEREAS, CytomX Therapeutics, Inc., having its principal place of business at 343 Oyster Point Blvd, Suite 100, South San Francisco, CA 94080 (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified in paragraph (1), (2) and/or (3); the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover damages, including royalties, for prior infringements of these applications; and any patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified in paragraph (1) (2) and/or (3);
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the

Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the applications for patent identified in paragraph (1), (2) and/or (3) or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover damages, including royalties, for prior infringements of any application(s) for patent identified in the preceding paragraphs (b)-(e); and

(g) any patent(s) of the United States or other countries that may be granted for or on any application(s) for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (*e.g.*, opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, *etc.*) without charge to the Assignor, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified in paragraph (1), (2) and/or (3) when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 8/26/2014

By: 
Olga Vasiljeva

IN WITNESS WHEREOF, I, Laura Johnson, hereby declare
(Print Name of Witness)


that I was personally present and did see the above named person duly sign and execute the assignment.


(Signature of Witness)

Date: 8/26/14

IN WITNESS WHEREOF, I, REBECCA TAYLOR, hereby declare
(Print Name of Witness)

that I was personally present and did see the above named person duly sign and execute the assignment.


(Signature of Witness)


Date: Aug 26, 2014

Date: 08/26/14

By: 
Elizabeth-Edna Mary Menendez

IN WITNESS WHEREOF, I, Laura Johnson, hereby declare
(Print Name of Witness)

that I was personally present and did see the above named person duly sign and execute the assignment.


(Signature of Witness)

Date: 8/26/14

IN WITNESS WHEREOF, I, REBECCA TAYLOR, hereby declare
(Print Name of Witness)

that I was personally present and did see the above named person duly sign and execute the assignment.


(Signature of Witness)

Date: 08/26/14

Date: 9/23/14

By: SMCCORK

Name: Sean McCarthy, D. Phil
Title: Chief Executive Officer
CytomX Therapeutics, Inc.

IN WITNESS WHEREOF, I, MARC BESMAN, hereby declare
(Print Name of Witness)

that I was personally present and did see the above named person duly sign and execute the assignment.

Marc
(Signature of Witness)

Date: Sep 23, 2014

IN WITNESS WHEREOF, I, Carol T Verser, hereby declare
(Print Name of Witness)

that I was personally present and did see the above named person duly sign and execute the assignment.

CT Verser
(Signature of Witness)

Date: 23 Sept 2014

109584010 v1